Navigation Links
Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development

Sunnyvale, CA (PRWEB) January 15, 2014

Freeslate, Inc., the leading provider of high throughput research solutions, today announced that Lupin Limited, one of India’s top five pharmaceutical companies, has received delivery of Freeslate’s CM Protégé PharmD System for high throughput solid form screening.

Lupin, headquartered in Mumbai, India, is focused on a wide range of quality, affordable generic and branded formulations and Active Pharmaceutical Ingredients (APIs) for the developed and developing markets of the world. Lupin has selected Freeslate’s CM Protégé PharmD System to accelerate polymorph screening, automating a formerly manual process and thereby increasing their throughput. The company expects to be able to perform more experiments with less material to support the expansion of their Novel Drug Discovery and Development Program.

“We are looking forward to using Freeslate’s CM Protégé PharmD System to accelerate our Novel Drug Discovery and Development Program,” said Mr. Raj Khamboj, President NDDS at Lupin. “We believe we will achieve a ten-fold improvement in throughput using the new system resulting in significant new discoveries that provide real benefits to patients.”

“Our CM Protégé PharmD System brings exciting capabilities to solid form screening and we’re pleased that Lupin sees it as a powerful tool for accelerating their development activities,” said John S. Senaldi, President and CEO of Freeslate. “As we focus on expansion in Asia and India, the CM Protégé PharmD System opens up opportunities for many more labs to adopt Freeslate’s cutting edge technology.”

Freeslate’s CM Protégé PharmD System brings the benefits of high throughput solid and solubility screening to a broader range of researchers with an easy-to-use, fully automated platform. The System can evaluate up to 384 crystallization conditions per run to rapidly turn around solid form screening projects. Solid forms can be analyzed by birefringence, x-ray powder diffraction, and Raman spectroscopy directly from the glass Universal Substrate without any manual manipulation of fragile crystals. Other analyses and additional experiments, such as solid form stability, can also be conducted directly on the glass Universal Substrate. Heating, cooling, and mixing on-deck allows for simultaneous slurry, precipitation, cooling, and evaporation experiments on a single platform.

The CM Protégé PharmD System uses Freeslate’s Lab Execution and Analysis (LEA) software for library design, protocol development/execution, data analysis, and reporting. This allows users to design complex experiments quickly using its logical, recipe-oriented approach, and experimental conditions can be linked to analytical data for easy viewing and reporting.

About Freeslate

Freeslate is a privately held company that provides products and related services for high throughput research. Based on its proprietary laboratory automation platforms, high throughput pressure reactors, and integrated Lab Execution and Analysis (LEA) software suite, the company enables dramatic gains in its customers’ productivity and innovation by delivering seamlessly integrated automation solutions. Freeslate leverages its scientific expertise through its team of Ph.D. scientists, engineers, and software developers with directly relevant experience in the industries it serves. Collaborating with customers for more than a decade, the business has provided high throughput research solutions for the pharmaceutical, chemical, and energy industries. The company is headquartered in Sunnyvale, California, with direct sales and service in North America, Europe, and Asia. For more information, visit

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Lupin Receives FDA Approval for Generic LYRICA(R)
2. Lupin élargit sa gamme
3. Lupin weitet Marken-Portfolio aus
4. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
5. Netsmart Selects Overland Park, Kansas, for New Office
6. Pharmaceutical Consortium Selects BioFortis Software to Manage Collaborative Clinical Data and Biobanking Activities
7. Maine Center for Creativity Selects Glenn Close and David Shaw to Receive Inaugural Maine Creative Industry Award
8. Aesthetics Pharmaceutical Company Selects 360 Vantage Closed Loop Marketing Solution for Apple iPad
9. Eaton Apothecary Selects Predictive Acquisition Cost (PAC) Drug Price Type
10. Bellicum Selects DATATRAK Solution for Drug Program
11. University of California, San Francisco (UCSF) Selects Conflict of Interest Management System
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... Matthew “Tex” VerMilyea, PhD, HCLD, has joined Texas ... oversee all IVF lab procedures as well as continue his research efforts into the ... miles to Auckland, New Zealand to bring home a High Complexity Clinical Laboratory Director ...
(Date:11/30/2015)... ... ... announced the opening of a new core patient care hub with the opening of ... are part of GSCG’s expansion efforts in Latin America. , Both the Arica and ... from around the world. , The clinics will be headed by Victor Perez, M.D. and ...
(Date:11/30/2015)... HOLLISTON, Mass. , Nov. 30, 2015 /PRNewswire/ ... HART ), a biotechnology company developing bioengineered ... has received written notification from The NASDAQ Stock ... minimum bid price requirements. The letter noted that ... of HART,s common stock having exceeded $1.00 per ...
(Date:11/30/2015)... Human Longevity, Inc. (HLI), the genomics-based, technology-driven ... Genomics, Inc., a leading genome informatics company offering highly ... The San Diego -based company has ... and Co-founder, Ashley Van Zeeland , Ph.D., who is ... of the deal were not disclosed. ...
Breaking Biology Technology:
(Date:11/18/2015)... , November 18, 2015 ... has published a new market report titled  Gesture Recognition ... and Forecast, 2015 - 2021. According to the report, the global ... and is anticipated to reach US$29.1 bn by 2021, ... North America dominated the ...
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):